Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system.
Hughes, R.O., Walker, J.K., Cubbage, J.W., Fobian, Y.M., Rogier, D.J., Heasley, S.E., Blevis-Bal, R.M., Benson, A.G., Owen, D.R., Jacobsen, E.J., Freskos, J.N., Molyneaux, J.M., Brown, D.L., Stallings, W.C., Acker, B.A., Maddux, T.M., Tollefson, M.B., Williams, J.M., Moon, J.B., Mischke, B.V., Rumsey, J.M., Zheng, Y., Macinnes, A., Bond, B.R., Yu, Y.(2009) Bioorg Med Chem Lett 19: 4092-4096
- PubMed: 19539468
- DOI: https://doi.org/10.1016/j.bmcl.2009.06.004
- Primary Citation of Related Structures:
3HC8 - PubMed Abstract:
Efforts to improve the potency and physical properties of the aminopyridiopyrazinone class of PDE5 inhibitors through modification of the core ring system are described. Five new ring systems are evaluated and features that impart improved potency and improved solubility are delineated.
Organizational Affiliation:
Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, MO 63017, USA. robert.o.hughes@pfizer.com